Share Email Print

Proceedings Paper

Development of anti-cadherin-17 antibody -IR700 conjugate for photodynamic therapy against gastrointestinal cancers
Author(s): Yick-Liang Lum; Dennis K. P. Ng; John M. Luk; Wing-Ping Fong
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

The lack of tumor specificity by photosensitizers often hampers the clinical application of photodynamic therapy (PDT). Delivery of photosensitizer to tumor based entirely on the enhanced permeability and retention effect could lead to nonspecific uptake of photosensitizer by normal tissue, causing adverse effect in patients. Accumulating evidence showed that the combination of antibody immunotherapy and PDT can complement each other to produce effective cancer-targeted photoimmunotherapy. IRDye 700DX (IR700) is a water-soluble phthalocyanine-based photosensitizer that can produce reactive oxygen species (ROS) efficiently upon light irradiation. Cadherin-17 (CDH17) is a cell surface antigen commonly overexpressed in gastrointestinal cancers. By conjugating IR700 to anti-CDH17 humanized monoclonal antibody (ARB102), the conjugate could target CDH17 positive cancer cells and achieve selective accumulation to induce potent cytotoxicity upon light irradiation.

Paper Details

Date Published: 7 August 2019
PDF: 6 pages
Proc. SPIE 11070, 17th International Photodynamic Association World Congress, 110702V (7 August 2019); doi: 10.1117/12.2525313
Show Author Affiliations
Yick-Liang Lum, The Chinese Univ. of Hong Kong (Hong Kong, China)
Dennis K. P. Ng, The Chinese Univ. of Hong Kong (Hong Kong, China)
John M. Luk, Arbele Ltd. (Hong Kong, China)
Arbele Corp. (United States)
Wing-Ping Fong, The Chinese Univ. of Hong Kong (Hong Kong, China)

Published in SPIE Proceedings Vol. 11070:
17th International Photodynamic Association World Congress
Tayyaba Hasan, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?